LOGIN  |  REGISTER
C4 Therapeutics

Politan Announces Shareholders Have Overwhelmingly Elected Both Its Director Nominees to Masimo's Board

June 26, 2023 | Last Trade: US$169.52 0.48 -0.28
  • Appreciates Support From Fellow Shareholders Demonstrating Clear Mandate For Change
  • Nominees Michelle Brennan and Quentin Koffey Are Ready to Work Constructively in the Masimo Boardroom to Benefit All Stakeholders

NEW YORK / Jun 26, 2023 / Business Wire / Politan Capital Management (together with its affiliates, “Politan”), a 9% shareholder of Masimo Corporation (“Masimo” or the “Company”) (NASDAQ: MASI), today commented on the outcome of the Company’s Annual Meeting of Stockholders (the “Annual Meeting”).

Both of Politan’s nominees – Michelle Brennan and Quentin Koffey – were overwhelmingly elected to the Board. Based on preliminary analysis from Politan’s proxy solicitor, each of Politan’s nominees received at least 70% of the total votes cast, with 17 of the top 20 (and 43 of the top 50) shareholders voting for both Politan’s candidates.1

Mr. Koffey, Managing Partner and Chief Investment Officer of Politan, stated:

“Michelle and I would like to thank our fellow shareholders for their support and engagement throughout this campaign, and we look forward to continuing this dialogue as directors. We believe this election represents a clear mandate from shareholders that significant change is needed at Masimo. We are now fully focused on putting the election behind us and working constructively with the incumbent directors to improve the Company’s corporate governance, enhance capital allocation and instill better strategic oversight. We look forward to helping Masimo reach its full potential for all its stakeholders.”

_________________________
1 Numbers exclude voting by company insiders.

Assertio

Stock Quote

Featured Stock

Compass Therapeutics

Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...

CLICK TO LEARN MORE

Featured Stock

Chimerix

Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....

CLICK TO LEARN MORE

End of content

No more pages to load

Next page

COPYRIGHT ©2023 HEALTH STOCKS HUB